OpGen, Inc. (Nasdaq: OPGN), a company that makes use of the power of molecular diagnostics and bioinformatics to treat infectious diseases, is showing strength in the pre-market trading today. News of peer-reviewed publication regarding faster identification of Covid-19 pneumonia-related infections has sparked a surge in activity. By 09:28 a.m. EST, the stock was buoyant at $2.24, up +14.29%.
What’s does the news say?
OpGen, Inc. combines molecular diagnostics and bioinformatics as well as clinical trials to manage infectious diseases. The company develops and commercializes molecular microbiology solutions together with its subsidiaries Curetis GmbH and Ares Genetics GmbH. This helps speed up clinician decision-making and decrease the spread of infections caused by multidrug-resistant microorganisms.
OpGen has created several products including Unyvero, Acuitas AMR Gene Panel, Acuitas Lighthouse, and the ARES Technology Platform with ARESdb, which uses next generation sequencing and artificial intelligence to predict antibiotic resistance.
Unyvero Pharma today announced the release of a new peer-reviewed publication that illustrates the capability of the Unyvero Hospitalized Pneumonia panel in detecting bacterial pathogens directly from low-respiratory samples. A bacterial co-infection can then be identified in five hours in patients hospitalized with COVID-19 pneumonia.
European Journal of Clinical Microbiology & Infectious Diseases has published the final findings of the study. Based on the results of the work, it is noteworthy that the Unyvero HPN panel is very accurate at detecting pathogens which are common in bacterial pneumonia with a 98% negative predictive value for the detection of pathogens. This may reduce unnecessary antibiotic usage and help to support efforts regarding antibiotic stewardship.